Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008
Cutaneous reactions to treatment with epidermal growth factor receptor (EGFR) inhibitor present a therapeutic challenge because there have been no controlled clinical trials to inform treatment decisions. We report herein the successful use of low-dose acitretin for treatment of an extensive pustular eruption induced by erlotinib.
A 57-year-old woman with metastatic pancreatic cancer presented with a 10-day history of severe erythematous pustules. The rapidly progressive eruption began on the face 4 days after erlotinib therapy, 100 mg/d, was initiated; it was pruritic and extremely painful.
Pomerantz RG, Chirinos RE, Falo LD, Geskin LJ. Acitretin for Treatment of EGFR Inhibitor–Induced Cutaneous Toxic Effects. Arch Dermatol. 2008;144(7):949–950. doi:10.1001/archderm.144.7.949
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: